FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808061703> ?p ?o ?g. }

• W2808061703 endingPage "1361" @default.
• W2808061703 startingPage "1355" @default.
• W2808061703 abstract "The intestinal barrier dysfunction is a critical pathological change in irritable bowel syndrome (IBS). The objective of this study was to evaluate the effect of Prim-O-glucosylcimifugin (POG) on intestinal barrier dysfunction and reveal possible molecular mechanisms. Human colon adenocarcinoma cell line (Caco-2) cell monolayers induced by tryptase (TRYP) were used to establish an intestinal barrier dysfunction model. Caco-2 cell monolayers from both functional and dysfunctional samples were treated with POG (30, 60 and 120 µg/mL) for 2, 8, 24, 36, 48 and 72 h. The Caco-2 cell monolayers were assessed by measurement of trans-epithelial electrical resistance (TEER) and percentage of fluorescein permeation (PFP). The expression of Protease Activated Receptor 2 (PAR-2) and myosin light chain kinase (MLCK) mRNA was analyzed by RT-PCR and the level of Zonula Occludens-1 (ZO-1) protein expression was determined by Western blot. In addition, the impact of POG on the distribution of the tight juction protein of Occludin was performed by immunofluorescence. Our results showed that POG elevated the TEER and decreased the PFP of the functional Caco-2 cell monolayers, as well as the dysfunctional Caco-2 cell monolayers. Furthermore, POG inhibited the expression of PAR-2 mRNA and MLCK mRNA and increased the level of ZO-1 protein expression in dysfunctional Caco-2 cells. The distribution of the Occludin proteins was ameliorated simultaneously. This study demonstrates that POG can enhance the intestinal barrier function of Caco-2 cell monolayers by inhibiting the expression of PAR-2 and MLCK and up-regulating the expression of ZO-1 protein, and ameliorated the distribution of Occludin protein." @default.
• W2808061703 created "2018-06-21" @default.
• W2808061703 creator A5000905149 @default.
• W2808061703 creator A5016219087 @default.
• W2808061703 creator A5016341425 @default.
• W2808061703 creator A5021172568 @default.
• W2808061703 creator A5026636116 @default.
• W2808061703 creator A5032960380 @default.
• W2808061703 creator A5053562979 @default.
• W2808061703 creator A5055352258 @default.
• W2808061703 creator A5073463218 @default.
• W2808061703 creator A5085643062 @default.
• W2808061703 creator A5085840076 @default.
• W2808061703 date "2018-09-01" @default.
• W2808061703 modified "2023-09-24" @default.
• W2808061703 title "The Effect of Prim-<i>O</i>-Glucosylcimifugin on Tryptase-Induced Intestinal Barrier Dysfunction in Caco-2 Cells" @default.
• W2808061703 cites W1573234344 @default.
• W2808061703 cites W1885931187 @default.
• W2808061703 cites W1904678284 @default.
• W2808061703 cites W1927073913 @default.
• W2808061703 cites W1977947961 @default.
• W2808061703 cites W1993753740 @default.
• W2808061703 cites W2002570028 @default.
• W2808061703 cites W2004723568 @default.
• W2808061703 cites W2012006259 @default.
• W2808061703 cites W2016753320 @default.
• W2808061703 cites W2018000139 @default.
• W2808061703 cites W2026756305 @default.
• W2808061703 cites W2036949982 @default.
• W2808061703 cites W2038328354 @default.
• W2808061703 cites W2041454039 @default.
• W2808061703 cites W2052532027 @default.
• W2808061703 cites W2052749982 @default.
• W2808061703 cites W2065163505 @default.
• W2808061703 cites W2066057598 @default.
• W2808061703 cites W2071745576 @default.
• W2808061703 cites W2081864509 @default.
• W2808061703 cites W2083521378 @default.
• W2808061703 cites W2100525799 @default.
• W2808061703 cites W2136346599 @default.
• W2808061703 cites W2147954623 @default.
• W2808061703 cites W2153538626 @default.
• W2808061703 cites W2153644577 @default.
• W2808061703 cites W2161238054 @default.
• W2808061703 cites W2170070882 @default.
• W2808061703 cites W2173892503 @default.
• W2808061703 cites W2289380928 @default.
• W2808061703 cites W2291181079 @default.
• W2808061703 cites W2313633163 @default.
• W2808061703 cites W2746698428 @default.
• W2808061703 doi "https://doi.org/10.1248/bpb.b18-00059" @default.
• W2808061703 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29910215" @default.
• W2808061703 hasPublicationYear "2018" @default.
• W2808061703 type Work @default.
• W2808061703 sameAs 2808061703 @default.
• W2808061703 citedByCount "8" @default.
• W2808061703 countsByYear W28080617032019 @default.
• W2808061703 countsByYear W28080617032021 @default.
• W2808061703 countsByYear W28080617032022 @default.
• W2808061703 countsByYear W28080617032023 @default.
• W2808061703 crossrefType "journal-article" @default.
• W2808061703 hasAuthorship W2808061703A5000905149 @default.
• W2808061703 hasAuthorship W2808061703A5016219087 @default.
• W2808061703 hasAuthorship W2808061703A5016341425 @default.
• W2808061703 hasAuthorship W2808061703A5021172568 @default.
• W2808061703 hasAuthorship W2808061703A5026636116 @default.
• W2808061703 hasAuthorship W2808061703A5032960380 @default.
• W2808061703 hasAuthorship W2808061703A5053562979 @default.
• W2808061703 hasAuthorship W2808061703A5055352258 @default.
• W2808061703 hasAuthorship W2808061703A5073463218 @default.
• W2808061703 hasAuthorship W2808061703A5085643062 @default.
• W2808061703 hasAuthorship W2808061703A5085840076 @default.
• W2808061703 hasBestOaLocation W28080617031 @default.
• W2808061703 hasConcept C104317684 @default.
• W2808061703 hasConcept C1491633281 @default.
• W2808061703 hasConcept C153911025 @default.
• W2808061703 hasConcept C177779419 @default.
• W2808061703 hasConcept C185592680 @default.
• W2808061703 hasConcept C193176779 @default.
• W2808061703 hasConcept C2775962179 @default.
• W2808061703 hasConcept C2776415932 @default.
• W2808061703 hasConcept C51911345 @default.
• W2808061703 hasConcept C55493867 @default.
• W2808061703 hasConcept C6997183 @default.
• W2808061703 hasConcept C8035138 @default.
• W2808061703 hasConcept C86803240 @default.
• W2808061703 hasConcept C95444343 @default.
• W2808061703 hasConceptScore W2808061703C104317684 @default.
• W2808061703 hasConceptScore W2808061703C1491633281 @default.
• W2808061703 hasConceptScore W2808061703C153911025 @default.
• W2808061703 hasConceptScore W2808061703C177779419 @default.
• W2808061703 hasConceptScore W2808061703C185592680 @default.
• W2808061703 hasConceptScore W2808061703C193176779 @default.
• W2808061703 hasConceptScore W2808061703C2775962179 @default.
• W2808061703 hasConceptScore W2808061703C2776415932 @default.
• W2808061703 hasConceptScore W2808061703C51911345 @default.
• W2808061703 hasConceptScore W2808061703C55493867 @default.
• W2808061703 hasConceptScore W2808061703C6997183 @default.

• next